Advanced search
Publication Cover
Future Oncology Volume 15, 2019 - Issue 34
Submit an article Journal homepage
1,425
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Is there a Role for Maintenance Therapy After Platinum Chemotherapy in Bladder Cancer in the Era of Immune Therapy?

Elie Rassy1 Department of Oncology, Saint Joseph University, Faculty of Medicine, Beirut, Lebanon
,
Tarek Assi1 Department of Oncology, Saint Joseph University, Faculty of Medicine, Beirut, LebanonCorrespondence[email protected]
&
Joseph Kattan1 Department of Oncology, Saint Joseph University, Faculty of Medicine, Beirut, Lebanon
Pages 3877-3879 | Received 15 Sep 2019, Accepted 04 Oct 2019, Published online: 15 Nov 2019

References

  • Malats N , RealFX. Epidemiology of bladder cancer. Hematolo. Oncol. Clin. North Am.29(2), 177–189 (2015).
  • Siegel RL , MillerKD, JemalA. Cancer statistics, 2019. CA A Cancer J. Clin.69(1), 7–34 (2019).
  • Rosenberg JE , CarrollPR, SmallEJ. Update on chemotherapy for advanced bladder cancer. J. Urol.174(1), 14–20 (2005).
  • Galsky MD , HahnNM, RosenbergJet al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J. Clin. Oncol.29(17), 2432–2438 (2011).
  • Bellmunt J , PetrylakDP. New therapeutic challenges in advanced bladder cancer. Semin. Oncol.39 (5),598–607 (2012).
  • Aoun F , RassyEE, AssiT, AlbisinniS, KatanJ. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. Immunotherapy9(5), 451–460 (2017).
  • Rassy EE , BakounyZ, AounFet al. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. Immunotherapy10(8), 657–663 (2018).
  • Paz-Ares L , de MarinisF, DediuMet al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, Phase III, randomised controlled trial. Lancet Oncol.13(3), 247–255 (2012).
  • Mirza MR , MonkBJ, HerrstedtJet al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Eng. J. Med.375(22), 2154–2164 (2016).
  • Ledermann J , HarterP, GourleyCet al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Eng. J. Med.366(15), 1382–1392 (2012).
  • Giuliani F , DeVita F, ColucciG, PiscontiS. Maintenance therapy in colon cancer. Cancer Treat. Rev.36, S42–S45 (2010).
  • Hoffman-Censits J , WongY-N. Perioperative and maintenance therapy after first-line therapy as paradigms for drug discovery in urothelial carcinoma. Clin. Genitourin. Cancer13(4), 302–308 (2015).
  • Bellmunt J , ThéodoreC, DemkovTet al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
  • García-Donas J , FontA, Pérez-ValderramaBet al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, Phase II trial. Lancet Oncol.18(5), 672–681 (2017).
  • Grivas PD , DaignaultS, TagawaSTet al. Double-blind, randomized, Phase II trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer120(5), 692–701 (2014).
  • Powles T , HuddartRA, ElliottTet al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. J. Clin. Oncol.35(1), 48–55 (2017).
  • Swann JB , SmythMJ. Immune surveillance of tumors. J. Clin. Invest.117(5), 1137–1146 (2007).
  • Kersten K , SalvagnoC, de VisserKE. Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front. Immunol.6, 516 (2015).
  • Shevchenko I , KarakhanovaS, SoltekSet al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int. J. Cancer133(1), 98–107 (2013).
  • de Biasi AR , Villena-VargasJ, AdusumilliPS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res.20(21), 5384–5391 (2014).
  • Galsky MD , PalSK, MortazaviAet al. Randomized double-blind Phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14–182. Am. Soc. Clin. Oncol.37(15), 4504 (2019).
  • Galsky MD , GrandeE, DavisIDet al. IMvigor130: a randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC). Am. Soc. Clin. Oncol.36, Suppl. 15 (2018).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.